Resistant Hypertension

Hypertension: A Companion to Braunwald's Heart Disease

Volumn , Issue , 2007, Pages 498-511

  Setaro, John F ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84882839036     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-1-4160-3053-9.50049-4     Document Type: Chapter

References (76)

1. Setaro JF, Black HR Refractory hypertension. N Engl J Med 1992, 327:543-547.
2. Chobanian AV, Bakris GL, Black HR, the National High Blood Pressure Education Program Coordinating Committee, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 Report. JAMA 2003, 289:2560-2572.
3. Hajjar I, Kotchen TA Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988-2000. JAMA 2003, 290:199-206.
4. Mokdad AH, Ford ES, Bowman BA, et al. Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. JAMA 2003, 289:76-79.
5. Isaksson H, Ostergrten J Prognosis in therapy-resistant hypertension. J Intern Med 1994, 236:643-649.
6. Cuspidi C, Macca G, Sampieri L, et al. High prevalence of cardiac and extracardiac organ damage in refractory hypertension. J Hypertens 2001, 19:2063-2070.
7. Staessen JA, Gasowski J, Wang JG, et al. Risks of untreated and treated systolic hypertension in the elderly: Meta-analysis of outcome trials. Lancet 2000, 355:865-872.
8. Kjeldsen SE, Dahlof B, Devereux RB, et al. Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy: A Losartan Intervention for Endpoint Reduction (LIFE) substudy. JAMA 2002, 288:1491-1498.
9. American Diabetes Association Hypertension management in adults with diabetes. Diabetes Care 2004, 27(Suppl 1):S65-S67.
10. K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Am J Kidney Dis 2004, 43(5 Suppl 2):1-290.
11. Lewington S, Clarke R, Qizilbash N, et al. Age-specific relevance of usual blood pressure to vascular mortality: A meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002, 360:1903-1913. for the Prospective Studies Collaboration.
12. Franklin SS, Jacobs MJ, Wong ND, et al. Predominance of isolated systolic hypertension among middle-aged and elderly US hypertensives: Analysis based on National Health and Nutrition Examination Survey (NHANES) III. Hypertension 2001, 37:869-874.
13. Hyman DJ, Pavlik VN Characteristics of patients with uncontrolled hypertension in the United States. N Engl J Med 2001, 345:479-486.
14. Staessen JA, Wang JG, Thijs L Cardiovascular prevention and blood pressure reduction: A quantitative overview updated until 1 March 2003. J Hypertens 2001, 21:1055-1076.
15. Adler AI, Stratton IM, Neil HA, et al. Association of systolic blood pressure with macrovascular and microvascular complications in type 2 diabetes (UKPDS 36). BMJ 2000, 321:412-419.
16. Hansson L, Zanchetti A, Carruthers SG, for the HOT Study Group, et al. Effects of intensive blood pressure lowering and low dose aspirin in patients with hypertension: Principal results of the Hypertension Optimal Treatment (HOT) randomized trial. Lancet 1998, 351:1755-1762.
17. Singer GM, Izhar M, Black HR Goal-oriented hypertension management: Translating clinical trials to practice. Hypertension 2002, 40:464-469.
18. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs. diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002, 288:2981-2997. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group.
19. Black HR, Elliott WJ, Grandits G, for the CONVINCE Research Group, et al. Principal results of the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) trial. JAMA 2003, 289:2073-2082.
20. Cushman WC, Ford CE, Cutler JA, et al. Success and predictors of blood pressure control in diverse North American settings: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). J Clin Hypertens (Greenwich) 2002, 4:393-404.
21. Pepine CJ, Handberg EM, Cooper-DeHoff RM, et al. A calcium antagonist vs. a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease: The International Verapamil-Trandolapril Study (INVEST). A randomized controlled trial. JAMA 2003, 290:2805-2816.
22. Dahlof B, Devereux RB, Kjeldsen S, et al. Cardiovascular morbidity and mortality in the Losartan Intervention for Endpoint Reduction in Hypertension study (LIFE): A randomized trial against atenolol. Lancet 2002, 359:995-1003.
23. Pickering TG, Hall JE, Appel LJ, et al. Recommendations for Blood Pressure Measurement in Humans and Experimental Animals: Part 1. Blood Pressure Measurement in Humans: A Statement for Professionals From the Subcommittee of Professional and Public Education of the American Heart Association Council on High Blood Pressure Research. Hypertension 2005, 45:142-161.
24. Wright JC, Looney SW Presence of positive Osier's maneuver in 3387 persons screened for the Systolic Hypertension in the Elderly Program (SHEP). J Hum Hypertens 1997, 11:285-829.
25. Staessen JA, Hond ED, Cells H, for the Treatment of Hypertension Based on Home or Office Blood Pressure (THOP) Trial Investigators, et al. Antihypertensive treatment based on blood pressure measurement at home or in the physician's office: A Randomized controlled trial. JAMA 2004, 291:955-964.
26. Yakovlevitch M, Black HR Resistant hypertension in a tertiary care clinic. Arch Intern Med 1991, 151:1786-1792.
27. Garg JP, Elliott WJ, Folker A, et al. Resistant hypertension revisited: A comparison of two university-based cohorts. Am J Hypertens 2005, 18:619-626.
28. Anderson GH, Blakeman N, Streeten DHP The effect of age on prevalence of secondary forms of hypertension in 4429 consecutively referred patients. J Hypertens 1995, 12:609-615.
29. Nishizaka MK, Calhoun DA Use of aldosterone antagonists in resistant hypertension. J Clin Hypertens (Greenwich) 2004, 6:458-460.
30. Agodoa L, Appel L, Bakris G, et al. Effect of ramipril versus amlodipine on renal outcomes in hypertensive nephrosclerosis: African American Study of Kidney Disease (AASK). A randomized controlled trial. JAMA 2001, 285:2719-2728.
31. Brenner BM, Cooper ME, DeZeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy (RENAAL). N Engl J Med 2001, 345:861-869.
32. Safian RD, Textor SC Renal-artery stenosis. N Engl J Med 2001, 344:431-442.
33. Mosso L, Carvajal C, Gonzalez A Primary aldosteronism and hypertensive disease. Hypertension 2003, 42:161-165.
34. Calhoun DA, Nishizaka MK, Zaman MA, et al. Hyperaldosteronism among black and white subjects with resistant hypertension. Hypertension 2002, 40:892-896.
35. Lim PO, Jung RT, MacDonald TM Is aldosterone the missing link in refractory hypertension? Aldosterone-to-renin ratio as a marker of inappropriate aldosterone activity. J Hum Hypertens 2002, 16:153-158.
36. Vasan RS, Evans JC, Larson MG, et al. Serum aldosterone and the incidence of hypertension in nonhypertensive persons. N Engl J Med 2004, 351:33-41.
37. Gallay BJ, Ahmad S, Xu L, et al. Screening for primary aldosteronism without discontinuing hypertensive medications: Plasma aldosterone-renin ratio. Am J Kidney Dis 2001, 37:699-705.
38. Nishizaka MK, Zaman MA, Calhoun DA Efficacy of low-dose spironolactone in subjects with resistant hypertension. Am J Hypertens 2003, 16:925-930.
39. Ouzan J, Perault C, Lincoff AM, et al. The role of spironolactone in the treatment of patients with refractory hypertension. Am J Hypertens 2002, 15:333-339.
40. Eisenhofer G. Biochemical diagnosis of pheochromocytoma. In: Pacak K (moderator). Recent advances in genetics, diagnosis, localization, and treatment of pheochromocytoma. Ann Intern Med. 2001;134:317-320.
41. Logan AG, Perlikowski SM, Mente A, et al. High prevalence of unrecognized sleep apnoea in drug-resistant hypertension. J Hypertens 2001, 19:2271-2277.
42. Pepperell JCT, Ramdassingh-Dow S, Costhwaite N, et al. Ambulatory blood pressure after therapeutic and subtherapeutic nasal continuous positive airway pressure for obstructive sleep apnea, a randomized parallel trial. Lancet 2002, 359:204-210.
43. Dhillon S, Chung SA, Fargher T, et al. Sleep apnea, hypertension, and the effects of continuous positive airway pressure. Am J Hypertens 2005, 18:594-600.
44. Goodfriend TL, Calhoun DA Resistant hypertension, obesity, sleep apnea, and aldosterone: Theory and therapy. Hypertension 2004, 43:518-524.
45. Davies SJ, Ghahramani P, Jackson PR, et al. Panic disorder, anxiety and depression in resistant hypertension: A case control study. J Hypertens 1997, 15:1077-1082.
46. Graves JW, Bloomfild RL, Buckalew VM Plasma volume in resistant hypertension: Guide to pathophysiology and therapy. Am J Med Sci 1989, 298:361-365.
47. Taler SJ, Textor SC, Augustine JE Resistant hypertension: Comparing hemodynamic management to specialist care. Hypertension 2002, 39:982-988.
48. Moser M Why are physicians not prescribing diuretics more frequently in the management of hypertension?. JAMA 1998, 279:1813-1816.
49. Heart Outcome Prevention Evaluation (HOPE) Study Investigators Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: Results of the HOPE Study and the MICRO HOPE substudy. Lancet 2000, 255:253-259.
50. Dickerson IEC, Hingorani AD, Ashby MJ, et al. Optimisation of antihypertensive treatment by crossover rotation of four major classes. Lancet 1999, 353:2008-2013.
51. Law MR, Wald NJ, Morris JK, Jordan RE Value of low dose combination treatment with blood pressure lowering drugs: Analysis of 354 randomised trials. BMJ 2003, 326:1427.
52. Saseen JJ, Carter BL, Brown TE, et al. Comparison of nifedipine alone and with diltiazem or verapamil in hypertension. Hypertension 1996, 28:109-114.
53. Mogensen CE, Neldam S, Tikkanen I, et al. Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: The Candesartan and Lisinopril Microalbuminuria (CALM) study. BMJ 2000, 321:1440-1444.
54. Black HR, Sollins JS, Garofalo JL The addition of doxazosin to the therapeutic regimen of hypertensive patients inadequately controlled with other antihypertensive medications: A randomized, placebo controlled study. Am J Hypertens 2000, 13:468-474.
55. Davies SJ, Jackson PR, Ramsay LE, Ghahramani P Drug intolerance due to non-specific adverse effects related to psychiatric morbidity in hypertensive patients. Arch Intern Med 2003, 163:592-600.
56. Berlowitz DR, Ash AS, Hickey EC, et al. Inadequate management of blood pressure in a hypertensive population. N Engl J Med 1998, 339:1957-1963.
57. Oliveria SA, Lapuerta P, McCarthy BD, et al. Physician-related barriers to the effective management of uncontrolled hypertension. Arch Intern Med 2002, 162:413-420.
58. Burnier M, Schneider MP, Chiolero A, et al. Electronic compliance monitoring in resistant hypertension: The basis for rational therapeutic decisions. J Hypertens 2001, 19:335-341.
59. Nuesch R, Schroeder K, Dieterle T, et al. Relation between insufficient response to antihypertensive treatment and poor compliance with treatment: A prospective case-control study. BMJ 2001, 323:142-146.
60. Haynes RB, McDonald HP, Garg AX Helping patients follow prescribed treatment: Clinical applications. JAMA 2002, 288:2880-2883.
61. McDonald HP, Garg AX, Haynes RB Interventions to enhance patient adherence to medication prescriptions: Scientific review. JAMA 2002, 288:2868-2879.
62. Lloyd-Jones DM, Evans JC, Larson A Differential control of systolic and diastolic blood pressure: Factors associated with lack of blood pressure control in the community. Hypertension 2000, 36:594-599.
63. Ferdinand KC Substance abuse and hypertension. J Clin Hypertens (Greenwich) 2000, 2:37-40.
64. Haller CA, Benowitz NL Adverse cardiovascular and central nervous system events associated with dietary supplements containing ephedra alkaloids. N Engl J Med 2000, 343:1833-1838.
65. Valli G, Giardina EGV Benefits, adverse effects and drug interactions of herbal remedies with cardiovascular effects. J Am Coll Cardiol 2002, 39:1083-1095.
66. DeSmet PAGM Herbal remedies. N Engl J Med 2002, 347:2046-2056.
67. Whelton A, Fort JG, Puma JA, for the SUCCESS VI Study Group, et al. Cyclooxygenase-2-specific inhibitors and cardiorenal function: A randomized, controlled trial of celecoxib and rofecoxib in older hypertensive osteoarthritis patients. Am J Ther 2001, 8:85-95.
68. Cho J, Cooke CE, Proveaux W A retrospective review of the effect of COX-2 inhibitors on blood pressure change. Am J Ther 2003, 10:311-317.
69. Sowers JR, White WB, Pitt B, for the Celecoxib Rofecoxib Efficacy and Safety in Comorbidities Evaluation Trial (CRESECENT) Investigators, et al. The effects of cyclooxygenase-2 inhibitors and nonsteroidal anti-inflammatory therapy on 24-hour blood pressure in patients with hypertension, osteoarthritis, and type 2 diabetes mellitus. Arch Intern Med 2005, 165:161-168.
70. Aw T-J, Haas SJ, Liew D, Krum H Meta-analysis of cyclooxygenase-2 inhibitors and their effects on blood pressure. Arch Intern Med 2005, 165:490-496.
71. Xin X, He J, Frontini MG, et al. Effects of alcohol reduction on blood pressure: A meta-analysis of randomized controlled trials. Hypertension 2001, 38:1112-1117.
72. Bramlage P, Pittrow D, Wittchen HU, et al. Hypertension in overweight and obese primary care patients is highly prevalent and poorly controlled. Am J Hypertens 2004, 17:904-910.
73. Martell N, Rodgriguez-Cerillo M, Grobbee DE, et al. High prevalence of secondary hypertension and insulin resistance in patients with refractory hypertension. Blood Press 2003, 12:149-154.
74. Wong ND, Pio JR, Franklin SS, et al. Preventing coronary events by optimal control of blood pressure and lipids in patients with the metabolic syndrome. Am J Cardiol 2003, 91:1421-1426.
75. Van Harmelen V, Elizalde M, Aripart P, et al. The association of human adipose angiotensinogen gene expression with abdominal fat distribution in obesity. Int J Ohes 2000, 24:673-678.
76. Appel LJ, Champagne CM, Harsha DW, et al. Effects of comprehensive lifestyle modification on blood pressure control: Main results of the PREMIER clinical trial. JAMA 2003, 289:2083-2093. for the PREMIER Collaborative Research Group.